Apollomics Inc.

Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies, particularly for difficult-to-treat and treatment-resistant cancers. The company utilizes targeted, immuno-oncology, and other innovative approaches to address various cancer indications, including acute myeloid leukemia, lung cancer, and brain cancer. Apollomics operates as a holding company incorporated in the Cayman Islands, with its primary business conducted at its U.S. headquarters in the San Francisco Bay Area and a discovery and development team located in Hangzhou, China. The company also has subsidiaries in Australia, Hong Kong, and China ¹.

The core business model revolves around the development of a pipeline of oncology product candidates, with a strategic focus on novel therapies. The company generates revenue through collaboration and licensing arrangements, as it currently has no products approved for commercial sale and thus no product sales revenue. Apollomics aims to identify development and commercialization partners to enable capital-efficient development programs and maximize market potential. A biomarker-driven diagnostic approach is adopted for patient screening to increase precision in identifying patients who may benefit from targeted therapy ².

Apollomics' product candidates are categorized into two groups based on their mechanisms of action: tumor inhibitors and immuno-oncology drugs. The tumor inhibitor candidates include vebreltinib (APL-101) and APL-102. Vebreltinib is the most advanced product candidate, a potent, oral active, highly selective c-Met inhibitor. It has received conditional approval from China's NMPA for NSCLC with Met Exon 14 skipping in November 2023, for gliomas with a PTPRZ1-MET fusion gene in April 2024, and for MET-amplified NSCLC in June 2025. Apollomics is investigating vebreltinib as a single agent for NSCLC and other advanced tumors with c-Met alterations, and as a combination therapy with EGFR inhibitors. It has also obtained FDA orphan drug designation for vebreltinib for the "treatment of non-small cell lung cancer with MET genomic tumor aberrations" ³.

The immuno-oncology product candidates include APL-501, APL-502, and APL-801. APL-501 is an anti-PD-1 antibody product candidate, with Phase 1 study data in advanced or relapsed/refractory solid tumors in Australia currently being analyzed. APL-502 is an anti-PD-L1 antibody product candidate, developed by partner Chia Tai Tian Qing (CTTQ) in China, and has been approved by China's NMPA for three indications: extensive-stage small cell lung cancer, recurrent/metastatic endometrial cancer, and late-stage unresectable or metastatic renal cell carcinoma. APL-801 is an early-stage candidate related to antibodies against CD40, developed in partnership with RevMab ⁴.

For the year ended December 31, 2025, Apollomics reported net losses of $10.9 million ⁵. The company used $10.4 million in net cash for operating activities ⁶. The balance of cash and cash equivalents as of December 31, 2025, was $3.3 million ⁷. The filing does not provide specific figures for total revenue, gross profit, gross margin percentage, operating income, operating margin, basic and diluted EPS, free cash flow, total debt, or net debt for the reported fiscal period.

During the year, Apollomics implemented cost reduction initiatives beginning in early 2024, prioritizing the development of vebreltinib and uproleselan. However, in May 2024, GlycoMimetics, the licensor of uproleselan in China, announced negative results from its pivotal Phase 3 study, leading Apollomics to close its own Phase 3 bridging study of uproleselan in China early. This resulted in an impairment loss of $10.0 million to write down the full value of the intangible asset for this program ⁸. In February 2025, Apollomics terminated the GlycoMimetics Agreement, effective May 2025. In November 2024, the license for APL-810 was terminated as part of pipeline prioritization, effective January 2025. On December 11, 2025, the Development and License Agreement for APL-122 with Edison Oncology Holding Corporation was formally terminated due to Edison's failure to meet material performance and reporting obligations ⁹. In late August 2025, due to severe cash constraints, former management announced the expected discontinuation of all activities related to the SPARTA clinical trial, but this was reversed following a $4.1 million PIPE financing on September 3, 2025, and the appointment of a new Board of Directors and executive management team ¹⁰. The company also transitioned significant operational functions to Taiwan while reducing headcount in China ¹¹.

Apollomics anticipates continuing to incur net losses and net operating cash outflows for the foreseeable future and states that it may never achieve or maintain profitability. The company's existing cash resources of $3.3 million as of December 31, 2025, even with the expected receipt of a $2.3 million outstanding receivable balance from LaunXP International, are not sufficient to meet its obligations through April 30, 2027 ¹². Subsequent to year-end, a $2.0 million unsecured convertible bridge loan was provided by the Chairman and CEO on March 30, 2026, further supporting liquidity ¹³. Apollomics will require additional capital, which it expects to seek through equity or debt financings or strategic partnerships, though these are not contractually committed ¹⁴.

A major growth area for Apollomics is the global development of vebreltinib, aiming to expand its potential across different c-Met alterations and tumor types. This includes developing vebreltinib for NSCLC with Met Exon 14 skipping, NSCLC with c-Met amplification, and pan-tumor c-Met fusions, including brain tumors with c-Met alterations. The company is actively enrolling new patients only for NSCLC with c-Met amplification in its ongoing Phase 2 global SPARTA study, and continues to follow previously-enrolled patients in other SPARTA cohorts. An investigator-sponsored study is also exploring combination therapy using vebreltinib with an EGFR inhibitor mutation to reduce treatment resistance ¹⁵. For GBM with PTPRZ1-Met fusion, Apollomics intends to discuss with the EMA in 2026 the approvability of vebreltinib in this indication ¹⁶.

Another growth vector involves expanding the drug portfolio through collaborations and partnerships. Apollomics actively seeks opportunities to in-license new assets and explore combination therapies to increase therapeutic benefit beyond monotherapy. The company plans to seek strategic partnerships with recognized industry players to make its innovative medicines accessible to patients and maximize market potential efficiently. This strategy is supported by a global network of clinical trial centers across more than ten jurisdictions, including the United States, China, Canada, England, France, Spain, Germany, Italy, Australia, Taiwan, and Singapore ¹⁷.

The company's operational outlook includes managing its reduced organizational size and capabilities, following a complete transition of executive leadership and Board of Directors in August and September 2025, and a reversal of prior wind-up plans. As of December 31, 2025, Apollomics had 14 full-time employees ¹⁸. The company must continue to implement and improve its managerial, operational, and financial systems and retain qualified personnel to effectively manage its operations ¹⁹.

Regarding capital allocation, Apollomics has paid $590,000 under the RevMab Agreement through 2025, including a $300,000 upfront payment, and incurred developmental expenses of nil in 2019, $140,000 in 2021, $150,000 in 2022, and nil in each of the years 2023 through 2025 ²⁰. Apollomics will also pay RevMab a royalty rate of 2% of net sales of mAb Products, subject to adjustment ²¹. The company is eligible to receive upfront payments totaling $10 million from LaunXP, of which $6.2 million has been paid as of December 31, 2025, with $2.3 million recorded as accounts receivable and an additional $1.5 million not yet billed ²². LaunXP has proposed a revised payment schedule contingent upon the completion of its own capital raising exercise, anticipated in Q2 2026 ²³.

Apollomics faces structural headwinds and execution risks, including the inherent uncertainty and high risk of failure in pharmaceutical drug development, which entails substantial upfront capital expenditures. The company's future profitability is dependent on the development of its pipeline products, and it has incurred significant losses since inception. The negative results from GlycoMimetics' Phase 3 study of uproleselan led to an impairment loss of $10.0 million and termination of the agreement, highlighting the risk of product candidate failure ²⁴. Delays or difficulties in patient enrollment in clinical trials, such as those experienced with the SPARTA MET amplification cohorts due to non-standard testing requirements, could adversely affect clinical development activities ²⁵.

Geographic, regulatory, and macro factors also pose constraints. The company's operations in China are subject to complex and rapidly evolving laws and regulations, including government control of currency conversion and potential restrictions on data transfer, which could impact funding and business expansion ²⁶. The regulatory approval processes of the FDA and other comparable authorities are lengthy, time-consuming, and unpredictable, with no guarantee of approval for product candidates. Changes in government regulations or practices, such as those related to healthcare reform in China or the FDA's Project Optimus and Project FrontRunner initiatives, could result in additional costs or delays ²⁷.

Apollomics faces material risks including its status as a pre-revenue biotechnology company with a history of losses, having incurred net losses of $10.9 million and used $10.4 million in net cash for operating activities for the year ended December 31, 2025 ²⁸. The company's existing cash and cash equivalents of $3.3 million as of December 31, 2025, are insufficient to meet obligations through April 30, 2027, indicating substantial doubt about its ability to continue as a going concern ²⁹. There is substantial dependence on the success of vebreltinib, its most advanced product candidate, and a lack of track record in launching and marketing commercial products. Clinical trials may fail to demonstrate safety and efficacy, as exemplified by the negative Phase 3 results for uproleselan, which led to an impairment loss of $10.0 million ³⁰. The company relies heavily on third parties for manufacturing and clinical trials, and any failure by these third parties could disrupt operations. Operations in China are subject to complex and rapidly evolving laws, government oversight, currency controls, and data protection regulations, which could restrict funding and expansion. Intellectual property rights are crucial, but patents may be challenged, narrowed, or invalidated, and the company may face costly litigation, such as the active litigation with Medpace, Inc. where Apollomics is seeking in excess of $2.0 million for alleged misappropriation and overcharges ³¹. Furthermore, the company is incurring significant expenses as a public company and has previously identified a material weakness in internal control over financial reporting as of December 31, 2023, which was remediated as of December 31, 2024 ³².

Management's overall tone emphasizes the company's strategic focus on developing novel oncology therapies for difficult-to-treat cancers and drug-resistant patients, leveraging a biomarker-driven diagnostic approach. They acknowledge the significant financial challenges, including a history of losses and the need for additional capital, stating that existing cash resources of $3.3 million as of December 31, 2025, are insufficient to meet obligations through April 30, 2027 ³³. However, they highlight the reversal of prior wind-up plans following a $4.1 million PIPE financing on September 3, 2025, and a $2.0 million unsecured convertible bridge loan from the Chairman and CEO on March 30, 2026, as crucial liquidity support ³⁴. Key strategic priorities include advancing the global development of vebreltinib, particularly for NSCLC with c-Met amplification, expanding the drug portfolio through collaborations and partnerships, and seeking development and commercialization partners to optimize efficiency and maximize market potential. They also emphasize building a global network of clinical trial centers to achieve enrollment goals and regulatory objectives across multiple regions ³⁵.